Jeffrey Sparling, MD
Interventional Cardiology · Oklahoma City, OKNPI 1679535223
Payments from drug & device makers
Across 888 payments — averaging $428.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$298K
- CSL Behring$63K
- Edwards Lifesciences$6K
- Abbott$4K
- Boston Scientific$4K
- Shockwave Medical, Inc$1K
- plus $4K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 438 | $298,438 |
| CSL Behring | 37 | $62,533 |
| Edwards Lifesciences | 60 | $6,357 |
| Abbott | 52 | $4,189 |
| Boston Scientific | 141 | $3,952 |
| Shockwave Medical, Inc | 17 | $1,103 |
| Abiomed | 19 | $1,023 |
| Philips North America LLC | 18 | $552 |
| Heartflow, Inc. | 8 | $496 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $424 |
| Atricure, Inc. | 4 | $346 |
| Penumbra, Inc. | 5 | $325 |
| E.r. Squibb & Sons, L.L.C. | 23 | $237 |
| Ascensia Diabetes Care US Inc. | 1 | $128 |
| Cordis US CORP. | 1 | $126 |
| Novartis | 5 | $97 |
| Esperion Therapeutics, Inc. | 5 | $97 |
| Amgen | 6 | $95 |
| Pfizer | 4 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Johnson & Johnson | 2 | $28 |
| Terumo Medical Corporation | 2 | $27 |
| Surmodics, Inc. | 2 | $26 |
| Boehringer Ingelheim | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
How this compares
$380,812 in reported general payments places this provider in the 95th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Oklahoma City
- Naeem TahirkheliOklahoma City$8.6M
- Mohammad GhaniOklahoma City$1.8M
- George ChrysantOklahoma City$873K
- Usman BaberOklahoma City$736K
- Thomas McGarryOklahoma City$153K
- Faisal LatifOklahoma City$129K
- Branislav SchifferdeckerOklahoma City$121K
- Mazen Abu-FadelOklahoma City$98K
- Dwayne SchmidtOklahoma City$79K
- Marcus SmithOklahoma City$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.